The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books
Feb 13, 2019 • 1h 10min
Ep38: Harlan and Chad Robins (Take 2)
The co-founders of Adaptive Biotechnologies on immune sequencing.
Jan 29, 2019 • 1h 10min
Ep37: Bonnie Anderson
Bonnie Anderson of Veracyte on genomic diagnostics.
Jan 15, 2019 • 1h 7min
Ep36: George Scangos
George Scangos on building an infectious disease company
Jan 2, 2019 • 1h
Ep35: Karen Akinsanya
Karen Akinsanya of Schrodinger on computational drug discovery
Dec 26, 2018 • 1h 15min
Ep34: Ron Renaud
Ron Renaud on developing messenger RNA therapies.
Dec 11, 2018 • 1h 13min
Ep33: Krishna Yeshwant
Krishna Yeshwant of GV on life at the intersection of tech and biotech.
Nov 28, 2018 • 1h
Ep32: Ned David
Ned David on extending human healthspan.
Nov 14, 2018 • 59min
Ep31: Julie Sunderland
Julie Sunderland on VC investing at the nexus of tech and biotech.
Oct 31, 2018 • 1h
Ep30: Barbara Weber
Barbara Weber on synthetic lethal cancer drug discovery
Oct 16, 2018 • 1h 10min
Ep29: John Wilbanks
John Wilbanks on making it easy to share biological data.
